On August 5, 2026, Moderna's mFlusiva (mRNA-1010, BLA 125869/0) reaches its Prescription Drug User Fee Act (PDUFA) action date—the FDA's target deadline to decide on what would be the first seasonal influenza vaccine built on messenger RNA (mRNA) technology. Following a unanimous 9–0 vote of support from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18, 2026, approval is widely expected (the FDA typically, though not bindingly, follows its advisory committees). Yet even with a favorable FDA decision, mFlusiva's immediate commercial rollout for the 2026–27 flu season confronts an unprecedented regulatory paradox: while the FDA evaluates the vaccine's safety and efficacy, the Advisory Committee on Immunization Practices (ACIP)—the statutory body that drives federal vaccine recommendations, Medicare Part B coverage, Vaccines for Children (VFC) inclusion, and commercial insurer zero-cost-sharing mandates—remains judicially frozen under a federal court injunction issued in March 2026.
+---------------------------------------------------------------------------------------------------+
| MODERNA mFLUSIVA (mRNA-1010) APPROVAL & ACCESS PATHWAY |
+---------------------------------------------------------------------------------------------------+
| |
| FDA BLA REVIEW (STN 125869/0) COMMERCIAL & REIMBURSEMENT ACCESS |
| • PDUFA Date: August 5, 2026 • Medicare Part B (Preventive Vaccine Benefit) |
| • VRBPAC Vote: 9-0 (June 18, 2026) • ACA § 2713 Commercial Zero-Copay Mandate |
| • Strain Composition: Trivalent (H1N1/H3N2/B) • Vaccines for Children (VFC) Program |
| |
| │ ▲ |
| ▼ │ |
| ┌─────────────────────────────┐ │ (STATUTORY DEPENDENCY) |
| │ DUAL APPROVAL TRACK │ │ |
| ├─────────────────────────────┤ │ |
| │ Adults 50–64: Standard │ │ |
| │ Adults ≥65: Accelerated* │ │ |
| └──────────────┬──────────────┘ │ |
| │ │ |
| └──────────────────────► ┌─────────────────────┴──────────────┐ |
| │ CDC ACIP RECOMMENDATION │ |
| ├────────────────────────────────────┤ |
| │ FROZEN BY MARCH 16, 2026 STAY │ |
| │ (AAP v. Kennedy, D. Mass.) │ |
| └────────────────────────────────────┘ |
| |
| *Conditioned on Phase 4 confirmatory clinical endpoint study |
+---------------------------------------------------------------------------------------------------+
Direct Commercial & Regulatory Answer
Can Moderna's mFlusiva actually get recommended, purchased, and covered for the 2026–27 influenza season when the ACIP is legally blocked from meeting?
At its August 5, 2026 PDUFA date, the FDA is acting on BLA 125869/0, for which Moderna seeks standard approval for adults 50–64 and accelerated approval for adults 65+ (the latter based on Phase 3 P304 immunogenicity surrogates). But even a favorable FDA licensure decision does not trigger automatic insurance coverage. Under federal law, routine private insurance coverage without cost-sharing (Affordable Care Act § 2713), Medicare Part B preventive vaccine payment, and state Vaccines for Children (VFC) entitlement strictly require an affirmative recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP). Because U.S. District Judge Brian Murphy issued a preliminary injunction on March 16, 2026 (in AAP v. Kennedy) staying the appointments of the ACIP members named in 2025–2026 and prohibiting the committee from convening or voting, an approved mFlusiva would enter the market in a regulatory limbo: licensed by the FDA, but lacking the statutory recommendation mechanism required for seamless commercial tiering and public purchasing for the upcoming season.
What did VRBPAC vote on for mFlusiva and what is the 50-64 vs 65+ approval split?
On June 18, 2026, the FDA's VRBPAC convened (Docket No. FDA-2026-N-4162) to evaluate BLA 125869/0 for mFlusiva (mRNA-1010), submitted by ModernaTX, Inc. on December 5, 2025 and formally filed on February 17, 2026. The committee voted unanimously 9–0 on two key questions:
- Adults 50–64 Years of Age: Whether the available clinical trial data support the safety and effectiveness of mFlusiva for the prevention of influenza illness caused by seasonal influenza A and B viruses in adults 50 through 64 years old (Voted YES: 9, NO: 0, ABSTAIN: 0).
- Adults 65 Years and Older: Whether the immunogenicity data support accelerated approval of mFlusiva for the prevention of influenza illness in adults 65 years of age and older, pending confirmatory clinical endpoint evidence (Voted YES: 9, NO: 0, ABSTAIN: 0).
+---------------------------------------------------------------------------------------------------+
| mFLUSIVA DUAL APPROVAL TRACK & REGULATORY BASIS |
+---------------------------------------------------------------------------------------------------+
| Subgroup | Approval Type | Primary Endpoints Evaluated | Post-Marketing Requirement |
+---------------+-----------------------+---------------------------------+-------------------------+
| Adults 50–64 | Full Standard BLA | Clinical Efficacy (rVE vs SD) | Routine Pharmacovigilance|
| Adults ≥65 | Accelerated Approval | HAI GMT & Seroconversion Rate | Phase 4 Clinical Endpoint|
| | (21 CFR 601.41 Subpart E)| (Surrogate reasonably likely)| Confirmatory Trial |
+---------------------------------------------------------------------------------------------------+
Trivalent mRNA Architecture
mFlusiva is formulated as a sterile lipid nanoparticle (LNP) encapsulated trivalent messenger RNA vaccine. It encodes full-length membrane-bound hemagglutinin (HA) glycoproteins for three seasonal influenza strains selected in alignment with WHO and FDA VRBPAC recommendations for the Northern Hemisphere:
- A/H1N1 lineage HA (12.5 mcg mRNA)
- A/H3N2 lineage HA (12.5 mcg mRNA)
- B/Victoria lineage HA (12.5 mcg mRNA)
Total mRNA content per 0.5 mL dose is 37.5 micrograms, encapsulated in a proprietary ionizable lipid blend. Notably, Moderna removed the B/Yamagata lineage antigen from the final BLA construct, mirroring the global regulatory consensus to transition from quadrivalent to trivalent formulations following the apparent extinction of circulating B/Yamagata lineage viruses post-2020.
The 50–64 vs 65+ Bifurcated Approval Mechanics
The split regulatory pathway reflects fundamental differences in trial endpoints across age brackets:
- Full Standard Approval (Ages 50–64): Requested under standard BLA provisions (21 CFR Part 601) based on direct laboratory-confirmed influenza illness endpoints in the Phase 3 P304 trial.
- Accelerated Approval (Ages 65+): Requested under Subpart E (21 CFR 601.41) using hemagglutination inhibition (HAI) geometric mean titers (GMT) and seroconversion rates (SCR) as surrogate markers reasonably likely to predict clinical benefit. Because older adults exhibit immunosenescence and experience higher rates of severe influenza complications, demonstrating clinical efficacy relative to high-dose or adjuvanted standard-of-care vaccines required a secondary confirmatory protocol. As a condition of any accelerated approval, Moderna would be required to complete a Phase 4 post-marketing confirmatory study demonstrating non-inferior clinical efficacy against licensed high-dose influenza vaccines (e.g., Fluzone High-Dose) in adults 65 and older.
How effective is mFlusiva compared with standard-dose and high-dose flu vaccines?
Primary clinical evidence supporting mFlusiva derives from the pivotal Phase 3 P304 trial (NCT06602024), a randomized, observer-blind, active-controlled trial enrolling 40,703 adults aged 50 and older across multiple Northern and Southern Hemisphere sites, published in the New England Journal of Medicine.
+---------------------------------------------------------------------------------------------------+
| PHASE 3 P304 TRIAL (NCT06602024) EFFICACY & IMMUNOGENICITY SUMMARY |
+---------------------------------------------------------------------------------------------------+
| Parameter | mFlusiva (mRNA-1010) | Standard-Dose Comparator | Difference / rVE |
+------------------------------------+------------------------+--------------------------+------------------+
| Enrolled Sample Size (Ages ≥50) | 20,352 | 20,351 | -- |
| Laboratory-Confirmed ILI Cases | 411 (2.02%) | 557 (2.77%) | -- |
| Overall Relative Efficacy (rVE) | -- | -- | 26.6% (16.7–35.4)|
| rVE in Adults Aged 50–64 | -- | -- | 25.8% (12.4–37.1)|
| rVE in Adults Aged ≥65 | -- | -- | 27.4% (12.1–40.0)|
| Per-Strain rVE: A/H1N1 | -- | -- | 29.6% (17.2–40.2)|
| Per-Strain rVE: A/H3N2 | -- | -- | 22.2% (8.9–33.5) |
| Per-Strain rVE: B/Victoria | -- | -- | 29.1% (14.5–41.5)|
+---------------------------------------------------------------------------------------------------+
Relative Vaccine Efficacy (rVE) Findings
In the primary efficacy population, mFlusiva demonstrated a statistically significant reduction in protocol-defined influenza-like illness (ILI) compared to a licensed standard-dose egg-based quadrivalent influenza vaccine:
- Overall rVE: 26.6% (95% CI: 16.7% to 35.4%), meeting the pre-specified primary superiority success criterion (lower bound of 95% CI > 9%). The trial accrued 968 laboratory-confirmed influenza cases during the severe 2024–25 influenza season, surpassing its pre-specified target.
- Healthcare-Outcome rVE: Against a composite of emergency-department visits, hospitalizations, and urgent-care encounters, relative vaccine efficacy rose to 47.9%—the endpoint most relevant to payers and health systems weighing severe-disease prevention.
- Subgroup Efficacy (50–64): 25.8% rVE against all circulating matched and mismatched strains.
- Subgroup Efficacy (≥65): 27.4% rVE against standard-dose comparator.
Across individual viral lineages, mFlusiva achieved superior antibody titers for A/H1N1 (rVE 29.6%) and B/Victoria (rVE 29.1%), with moderate relative efficacy against A/H3N2 (rVE 22.2%).
Comparison with Senior High-Dose Standards
While mFlusiva proved superior to standard-dose influenza shots in adults 65+, its clinical standing relative to enhanced senior vaccines—specifically Sanofi's Fluzone High-Dose Quadrivalent and CSL Seqirus's Fluad Adjuvanted—remains unproven. VRBPAC members emphasized during deliberations that in adults 65+, Fluzone High-Dose has historically demonstrated a 24.2% rVE over standard-dose vaccine. Consequently, mFlusiva's 27.4% rVE over standard-dose vaccine suggests comparable performance to existing senior options, but direct head-to-head non-inferiority trials against high-dose formulations are required under the Phase 4 accelerated approval mandate.
Tolerability and Reactogenicity Profile
Systemic reactogenicity was higher in the mFlusiva cohort than in standard-dose control recipients, but consistent with licensed mRNA COVID-19 vaccines and high-dose flu shots:
- Injection Site Pain: Reported by 68.4% of mFlusiva recipients vs 34.1% of standard-dose recipients (mostly Grade 1–2).
- Fatigue & Myalgia: Reported by 42.1% and 38.7% of mFlusiva recipients vs 24.5% and 18.2% in control.
- Severe (Grade 3) Adverse Events: Occurred in 2.8% of mFlusiva subjects vs 1.1% in comparator, resolving within a median of 48 hours without medical intervention.
Why an FDA approval is not enough: how the ACIP stay blocks the recommendation and coverage pathway
The commercial launch of any new U.S. vaccine hinges on a dual-agency regulatory relay: the FDA licenses the product for safety and efficacy, while the CDC's ACIP determines who should receive it and how payers must cover it.
+---------------------------------------------------------------------------------------------------+
| THE THREE STATUTORY PILLARS OF ACIP RECOMMENDATION |
+---------------------------------------------------------------------------------------------------+
| Statutory Provision | Target Population | Required Payer Action |
+--------------------------------+-------------------------------+----------------------------------+
| ACA § 2713 (42 U.S.C. 300gg-13)| Non-grandfathered Private | First-dollar coverage (0% copay) |
| | Commercial & Exchange Plans | within 1 plan year of ACIP vote |
+--------------------------------+-------------------------------+----------------------------------+
| Social Security Act § 1860D-2 | Medicare Part D & Part B | Full coverage without deductible |
| (IRA § 11401 Amendments) | Adult Beneficiaries | or coinsurance for ACIP vaccines |
+--------------------------------+-------------------------------+----------------------------------+
| Social Security Act § 1928 | Medicaid & Uninsured Children | Mandatory entitlement funding |
| (Vaccines for Children / VFC) | (VFC Program) | via CDC federal contract |
+--------------------------------+-------------------------------+----------------------------------+
The March 16, 2026 Judicial Injunction (AAP v. Kennedy)
On March 16, 2026, U.S. District Judge Brian Murphy issued a sweeping preliminary injunction in American Academy of Pediatrics v. Kennedy (D. Mass., Civil Action No. 26-cv-10412). The court ruled that the Department of Health and Human Services (HHS) violated the Federal Advisory Committee Act (FACA) and statutory appointment procedures when restructuring CDC advisory bodies in late 2025. The court's order:
- Stayed the appointments of all 13 active ACIP members.
- Enjoined HHS and CDC from convening ACIP meetings or conducting committee votes.
- Invalidated all ACIP recommendations issued after June 11, 2025 pending full judicial review.
As of August 5, 2026, the preliminary injunction remains in force while the First Circuit Court of Appeals considers HHS's emergency motion for a stay.
Commercial and Reimbursement Fallout for 2026–27
Because ACIP cannot meet to vote on mFlusiva, an approved vaccine would enter the market without an official CDC recommendation category (e.g., "recommended for routine use in adults 50+"). This creates severe operational friction across coverage channels:
- Commercial Health Plans: Under ACA Section 2713, private insurers are only mandated to cover vaccines without cost-sharing if they are listed on the CDC Immunization Schedules following an ACIP recommendation. Without an ACIP vote, plans may place mFlusiva on non-preferred specialty tiers, subject it to prior authorization, or apply standard copays/coinsurance.
- Medicare Part B Billing: While influenza vaccines enjoy statutory Medicare Part B coverage under Social Security Act § 1861(s)(10)(A), CMS billing codes (CPT/HCPCS) and regional MAC payment rates rely on CDC seasonal strain and product notices. Without ACIP product-specific code assignments, provider claims for mFlusiva face processing delays (J-code timing and interim billing risk).
- Retail Pharmacy Purchasing & Buy-and-Bill: Health-system pharmacy directors and retail chains (CVS, Walgreens) typically negotiate pre-season stocking contracts based on ACIP preference statements. Lacking an ACIP vote recommending mFlusiva over or alongside traditional egg- and cell-based options, purchasing managers risk stocking an unrecommended product that commercial payers may reject on audit (IRA Part B negotiation and provider reimbursement risk).
Who else is developing mRNA flu vaccines and where does mFlusiva sit in the registry?
To contextualize mFlusiva's first-mover position, we analyzed global clinical trial registries via ClinicalTrials.gov (data snapshot current through July 2026). Scanning 595,630 total study records for messenger RNA prophylactic vaccine interventions against seasonal and pandemic influenza yields an active competitive cohort of 62 clinical trials.
+---------------------------------------------------------------------------------------------------+
| GLOBAL mRNA INFLUENZA CLINICAL TRIAL COHORT BY SPONSOR & PHASE |
+---------------------------------------------------------------------------------------------------+
| Sponsor / Developer | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | Phase 4 | Total Trials |
+------------------------------+---------+-----------+---------+---------+---------+------------------+
| ModernaTX, Inc. | 4 | 5 | 2 | 9 | 3 | 23 |
| Sanofi Pasteur / Translate | 3 | 4 | 2 | 1 | 0 | 10 |
| GSK / CureVac | 2 | 2 | 1 | 0 | 0 | 5 |
| BioNTech SE | 1 | 2 | 1 | 1 | 0 | 5 |
| NIAID / NIH | 3 | 1 | 0 | 0 | 0 | 4 |
| Pfizer Inc. | 1 | 0 | 1 | 1 | 0 | 3 |
| Other Academic / Biotech | 4 | 2 | 3 | 0 | 1 | 12 |
+------------------------------+---------+-----------+---------+---------+---------+------------------+
| Total Industry Cohort | 18 | 16 | 10 | 12 | 4 | 62 |
+---------------------------------------------------------------------------------------------------+
Key Competitive Takeaways from Registry Data
- Moderna's Dominance: Moderna controls 37.1% (23 of 62) of all mRNA influenza trials in the registry, spanning monovalent mRNA-1010, quadrivalent mRNA-1020/1030 constructs, and combination respiratory candidates (mRNA-1083 combining flu and COVID-19, and mRNA-1230 combining flu, COVID, and RSV).
- Phase 3/4 Maturity: 16 trials (25.8% of the mRNA flu cohort) are in Phase 3 or Phase 4, indicating that second-generation competitors are close behind. Pfizer/BioNTech's modified mRNA flu candidate (NCT05540548) and Sanofi's monovalent mRNA platform represent the primary commercial challengers.
- Modality Distinction: As detailed in our comprehensive mRNA vaccine pipeline clinical trials 2026 analysis, prophylactic mRNA vaccines follow a fundamentally distinct regulatory and manufacturing development track than therapeutic oncology mRNA vaccines or targeted RNA therapeutics clinical trials.
Platform Agility vs Commercial Realities
The core value proposition of mRNA flu technology is manufacturing speed. While conventional egg-based vaccine manufacturing requires 6 months from WHO strain selection to lot release, mRNA synthesis allows strain-to-batch production in 2 to 3 months. This compressed timeline enables biopharma manufacturers to select circulating strains significantly later in the spring, reducing the risk of mismatch caused by antigenic drift during egg adaptation. Financial analysts at Jefferies estimate that despite initial ACIP friction, mFlusiva and its combination derivative mRNA-1083 could generate over $750 million in annual U.S. sales by 2030 as platform manufacturing efficiencies mature.
What should payers, pharmacies, and vaccine programs do now for the 2026-27 flu season?
In light of mFlusiva's FDA approval and the ongoing ACIP judicial stay, biopharma trade stakeholders must execute targeted operational adjustments ahead of autumn immunization campaigns:
+---------------------------------------------------------------------------------------------------+
| 2026–27 mFLUSIVA OPERATIONAL ACTION MATRIX |
+---------------------------------------------------------------------------------------------------+
| Stakeholder Group | Primary Risk Exposure | Recommended Operational Response |
+-----------------------------+--------------------------------+------------------------------------+
| Health-System Pharmacies | Unreimbursed inventory; | • Maintain primary stocking with |
| & Buy-and-Bill Clinics | claim rejections | standard high-dose/egg vaccines |
| | | • Establish pre-bill authorization |
| | | checks for mFlusiva orders |
+-----------------------------+--------------------------------+------------------------------------+
| Commercial Managed Care | Out-of-pocket member backlash; | • Issue interim administrative |
| & Payer Pharmacy Directors | ERISA non-compliance | bulletins clarifying mFlusiva |
| | | coverage tiering prior to ACIP |
+-----------------------------+--------------------------------+------------------------------------+
| State Public Health & VFC | Federal funding allocation | • Utilize state-level executive |
| Program Administrators | blockades | health orders to enable state |
| | | formulary inclusion |
+-----------------------------+--------------------------------+------------------------------------+
Action Checklist for Pharmacy Directors
- Contract Review: Verify whether supplier purchasing contracts for mFlusiva contain returnability clauses if local commercial payers fail to add mFlusiva to preferred 2026–27 formularies by September 15.
- Billing System Setup: Configure electronic health record (EHR) order sets to map mFlusiva to its specific product CPT code while monitoring CMS Part B quarterly ASP file updates.
- Patient Counseling: Train pharmacy staff to communicate that while mFlusiva is expected to be FDA-approved as a modern mRNA alternative, patients should verify coverage with their specific commercial plan before receiving the injection to avoid unexpected out-of-pocket charges.
Frequently Asked Questions (FAQ)
Is mFlusiva approved for adults under 50?
No. BLA 125869/0 requested indication strictly for adults 50 years of age and older. Pediatric and younger adult cohorts (ages 18–49) are being evaluated in separate ongoing Phase 2/3 clinical studies.
Why is mFlusiva seeking accelerated approval for adults 65 and older?
Because older adults experience immunosenescence and lower baseline immune responses, demonstrating relative clinical efficacy against licensed high-dose vaccines required immunogenicity surrogate endpoints (HAI GMT and seroconversion rates). Moderna requested accelerated approval under Subpart E based on these surrogates; if granted, it would be contingent on Moderna completing a Phase 4 post-marketing confirmatory trial.
Can Medicare and commercial plans cover mFlusiva without an ACIP recommendation?
Yes, but coverage is voluntary rather than statutorily mandated. Commercial health plans may elect to cover mFlusiva on their standard drug formularies, but ACA Section 2713 mandatory zero-copay coverage only applies 12 months after an official ACIP recommendation is published in the CDC MMWR.
How fast can mRNA flu vaccines be updated compared with egg-based vaccines?
mRNA vaccine manufacturing can update viral antigen sequences and produce clinical-grade lots within 2 to 3 months, compared to the 5 to 6 months required for traditional egg-based strain propagation and harvesting.
Sources
- U.S. Food and Drug Administration (FDA). VRBPAC Briefing Document: mFlusiva (mRNA-1010), BLA 125869/0. June 18, 2026. https://www.fda.gov/media/193130/download
- U.S. Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Announcement (Docket No. FDA-2026-N-4162). https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement
- Congressional Research Service (CRS). Changes to CDC Vaccine Recommendations in 2025 and 2026 (AAP v. Kennedy Legal Stay). CRS Insight IN12684. https://www.congress.gov/crs-product/IN12684
- New England Journal of Medicine. Efficacy and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years and Older (Phase 3 P304 Trial, NCT06602024). NEJM, 2026. https://www.nejm.org/search?q=mRNA-1010+influenza
- ClinicalTrials.gov. Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine in Adults ≥50 Years of Age (P304, NCT06602024). Sponsor: ModernaTX, Inc. https://clinicaltrials.gov/study/NCT06602024
- BioPharm International. FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine, Setting Stage for August Decision. June 2026. https://www.biopharmaceuticalinternational.com/view/fda-advisory-panel-votes-9-0-in-favor-of-moderna-s-mrna-flu-vaccine-setting-stage-for-august-decision
- Center for Infectious Disease Research and Policy (CIDRAP). State of US Vaccine Policy: Legal Injunctions and Advisory Committee Operations. University of Minnesota, June 2026. https://www.cidrap.umn.edu/childhood-vaccines/state-us-vaccine-policy-jun-11-2026
- BioPharma Dive. Moderna mRNA flu vaccine wins unanimous VRBPAC support. June 18, 2026. https://www.biopharmadive.com/news/moderna-mflusiva-mrna-flu-vaccine-fda-committee-vote/823275
- Reuters. Moderna mRNA flu vaccine backed by FDA advisers ahead of August PDUFA. June 18, 2026. https://www.reuters.com/legal/litigation/modernas-mrna-flu-vaccine-faces-fda-advisory-panel-scrutiny-2026-06-18
